Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
PR Newswire —
CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer,...